96 related articles for article (PubMed ID: 11850642)
1. Pharmacokinetics of Nisoldipine Coat--Core Formulation in Subjects with Liver Cirrhosis.
Shah A; Krol G; Sundaresan P; Lettieri J; Falk R; Lasseter K; Heller AH
Am J Ther; 1995 Jan; 2(1):15-19. PubMed ID: 11850642
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of the controlled-release nisoldipine coat-core tablet formulation.
Heinig R; Ahr G; Hayauchi Y; Kuhlmann J
Int J Clin Pharmacol Ther; 1997 Aug; 35(8):341-51. PubMed ID: 9266290
[TBL] [Abstract][Full Text] [Related]
3. Nisoldipine coat-core. A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of ischaemic heart disease.
Langtry HD; Spencer CM
Drugs; 1997 May; 53(5):867-84. PubMed ID: 9129871
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and tolerability of nisoldipine coat-core formulation in the treatment of essential hypertension: The South African Multicenter ANCHOR Study. Ambulatory Nisoldipine Coat-Core Hypertension Outpatient Response (ANCHOR) Investigators.
Opie LH; Müller FO; Myburgh DP; Rosendorff C; Sareli P; Seedat YK; Weich DJ; Luus HG
Am J Hypertens; 1997 Mar; 10(3):250-60. PubMed ID: 9056681
[TBL] [Abstract][Full Text] [Related]
5. Rapid-release and coat-core formulations of nisoldipine in treatment of hypertension, angina, and heart failure.
Hamilton SF; Houle LM; Thadani U
Heart Dis; 1999; 1(5):279-88. PubMed ID: 11720635
[TBL] [Abstract][Full Text] [Related]
6. Clinical pharmacokinetics of nisoldipine coat-core.
Heinig R
Clin Pharmacokinet; 1998 Sep; 35(3):191-208. PubMed ID: 9784933
[TBL] [Abstract][Full Text] [Related]
7. Nisoldipine CC: clinical experience in hypertension.
Langan J; Rodríguez-Mañas L; Sareli P; Heinig R
Cardiology; 1997; 88 Suppl 1():56-62; discussion 63-5. PubMed ID: 9118169
[TBL] [Abstract][Full Text] [Related]
8. Multiple dose pharmacokinetics of four different doses of nisoldipine in hypertensive patients.
Chandler MH; Clifton GD; Lettieri JT; Mazzu AL; Allington DR; Thieneman AC; Foster TS; Harrison MR
J Clin Pharmacol; 1992 Jun; 32(6):571-5. PubMed ID: 1634646
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic-pharmacodynamic modelling as a tool to evaluate the clinical relevance of a drug-food interaction for a nisoldipine controlled-release dosage form.
Schaefer HG; Heinig R; Ahr G; Adelmann H; Tetzloff W; Kuhlmann J
Eur J Clin Pharmacol; 1997; 51(6):473-80. PubMed ID: 9112062
[TBL] [Abstract][Full Text] [Related]
10. Nisoldipine: kinetics and effects on blood pressure and heart rate in patients with liver cirrhosis after intravenous and oral administration.
van Harten J; van Brummelen P; Wilson JH; Lodewijks MT; Breimer DD
Eur J Clin Pharmacol; 1988; 34(4):387-94. PubMed ID: 3402524
[TBL] [Abstract][Full Text] [Related]
11. Single- and multiple-dose pharmacokinetics of a hydrocodone bitartrate extended-release tablet formulated with abuse-deterrence technology in healthy, naltrexone-blocked volunteers.
Darwish M; Yang R; Tracewell W; Robertson P; Bond M
Clin Ther; 2015 Feb; 37(2):390-401. PubMed ID: 25542074
[TBL] [Abstract][Full Text] [Related]
12. Clinical pharmacology of nisoldipine coat core.
Zannad F
Am J Cardiol; 1995 Apr; 75(13):41E-45E. PubMed ID: 7726124
[TBL] [Abstract][Full Text] [Related]
13. The effect of age and liver disease on the pharmacokinetics of the calcium antagonist, nisoldipine.
Davidsson GK; Edwards JS; Davidson C
Curr Med Res Opin; 1995; 13(5):285-97. PubMed ID: 7555038
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of a once-daily extended-release formulation of pramipexole in healthy male volunteers: three studies.
Jenner P; Könen-Bergmann M; Schepers C; Haertter S
Clin Ther; 2009 Nov; 31(11):2698-711. PubMed ID: 20110012
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic and pharmacodynamic characteristics of aranidipine sustained-release, enteric-coated tablets in healthy Chinese men: a phase I, randomized, open-label, single- and multiple-dose study.
Jiang J; Tian L; Huang Y; Li Y; Xu L
Clin Ther; 2008 Jul; 30(7):1290-9. PubMed ID: 18691988
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of duloxetine hydrochloride enteric-coated tablets in healthy Chinese volunteers: a randomized, open-label, single- and multiple-dose study.
Zhao RK; Cheng G; Tang J; Song J; Peng WX
Clin Ther; 2009 May; 31(5):1022-36. PubMed ID: 19539103
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of single-dose and multiple-dose memantine in healthy chinese volunteers using an analytic method of liquid chromatography-tandem mass spectrometry.
Liu MY; Meng SN; Wu HZ; Wang S; Wei MJ
Clin Ther; 2008 Apr; 30(4):641-53. PubMed ID: 18498913
[TBL] [Abstract][Full Text] [Related]
18. Nisoldipine coat-core and heart rate response during treatment of hypertension.
Zannad F
Int J Clin Pract; 1999; 53(1):65-71. PubMed ID: 10344070
[TBL] [Abstract][Full Text] [Related]
19. The contribution of nisoldipine-induced changes in liver blood flow to its pharmacokinetics after oral administration.
van Harten J; Burggraaf J; Danhof M; van Brummelen P; Breimer DD
Br J Clin Pharmacol; 1989 May; 27(5):581-6. PubMed ID: 2757881
[TBL] [Abstract][Full Text] [Related]
20. Effect of eslicarbazepine acetate on the steady-state pharmacokinetics and pharmacodynamics of warfarin in healthy subjects during a three-stage, open-label, multiple-dose, single-period study.
Vaz-da-Silva M; Almeida L; Falcão A; Soares E; Maia J; Nunes T; Soares-da-Silva P
Clin Ther; 2010 Jan; 32(1):179-92. PubMed ID: 20171423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
